COMPLAINT FILED AGAINST ATHEROGENICS

Schatz & Nobel has filed a lawsuit seeking class action against AtheroGenics alleging the company violated federal securities laws by issuing false or misleading public statements. The Hartford, Conn.-based law firm filed the complaint in the U.S. District Court for the Southern District of New York. It alleges that Atlanta-based AtheroGenics misrepresented the results of an inconclusive and limited study of its experimental drug AGI-1067.

Atlanta Business Chronicle (http://www.bizjournals.com/atlanta/stories/2005/01/03/daily44.html)